Zydus Lifesciences acquires UK LiqMeds Group for 68 mn pounds

Published on:

Chennai, Oct 31 (IANS) Indian pharmaceutical major Zydus Lifesciences Ltd on Tuesday said it has signed an agreement to acquire the UK-headquartered LiqMeds Group of companies for a cash consideration of 68 million pounds.

In a regulatory filing, Zydus Lifesciences said the acquisition will be by its UK subsidiary Zydus Pharmaceuticals UK Ltd.

According to Zydus Lifesciences, the acquisition of LiqMeds group consists of five companies having specialisation in development, manufacturing, and supply of oral liquid products. The group’s subsidiary LM Manufacturing Ltd (LMML), has an oral liquids manufacturing site at Weedon, Northampton, UK, which supplies products to the US and UK markets.

As per the acquisition deal, the Indian company will pay 45.8 million pounds to the sellers towards cost of acquisition of the 5.3 million pounds LiqMeds group. The balance 22.2 million pounds will be utilised for settlement of indebtedness of LiqMeds Group as on the date of completion.

In addition, additional amounts will be paid, in tranches, over next three calendar years, depending on achievement of certain agreed milestones, the Indian company said.

Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.

Except for the headline and photo, this story has not been edited by THIP Media staff and is published from a syndicated feed / newswire service.